Advice
In the absence of a submission from the holder of the marketing authorisation.
Risedronate sodium (Actonel) is not recommended for use within NHSScotland for the treatment of osteoporosis in men at high risk of fractures.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- risedronate sodium (Actonel)
- SMC ID:
- 424/07
- Indication:
- osteoporosis in men at high risk of fractures
- Pharmaceutical company
- Procter and Gamble
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 December 2007